Figure 1.

Enhanced tumor growth and reduced TILs in mice i.t. injected with PDPN⁺ LNSCs. (A) Immunohistochemical LYVE-1, ER-TR7, PDPN, and DAPI staining of day 14 tumor sections is shown. (B) Gating strategy for the isolation of PDPN⁺ LNSCs from LNs of naive mice is presented. (C) Experimental outline for B16/F10 and PDPN⁺ LNSCs in vivo administration. Mice were injected s.c. on day 0 with 3 × 10⁵ B16/F10 and 5–10 × 10⁴ PDPN⁺ LNSCs sorted from LNs of naïve mice. On day 10 mice received an i.t. injection of 5–10 × 10⁴ PDPN⁺ LNSCs. On day 15 mice were sacrificed and their TILs were analyzed. (D) Mean and standard deviation of tumor volume of mice treated as in (B) 15 d after tumor inoculation are denoted. (E) Gating strategy, mean, and standard deviation of CD4⁺ and CD8⁺ T cell numbers per 5 × 10⁵ total tumor cells are shown. Means were calculated from three independent experiments. Numbers on FACS plots denote frequency of gated population. *p < 0.05, **p < 0.005.